Yung Lyou, MD, PhD, discusses emerging biomarkers in prostate cancer.
Yung Lyou, MD, PhD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses emerging biomarkers in prostate cancer.
One advancement being made with regard to biomarkers is the uptake of liquid biopsies for men with prostate cancer, Lyou says. Rather than relying solely on invasive, tumor-based tissue testing, liquid biopsy offers a less invasive, blood-based option for genomic assessment, Lyou explains.
Additionally, biomarkers such as soluble PD-L1 and FGFR3 are being evaluated for use with blood-based biopsies, Lyou says. Regarding tissue-based testing, stromal signature TFG-ß could offer a potentially actionable target in prostate cancer, concludes Lyou.